Amicus Therapeutics Inc [NASDAQ: FOLD] plunged by -$0.14 during the normal trading session on while it closed the day at $6.10.
Amicus Therapeutics Inc stock has also loss -7.44% of its value over the past 7 days. However, FOLD stock has declined by -32.45% in the 3 months of the year. Over the past six months meanwhile, it has lost -35.79% and lost -35.24% year-on date.
The market cap for FOLD stock reached $1.88 billion, with 307.92 million shares outstanding and 297.28 million shares in the current float. Compared to the average trading volume of 4.03M shares, FOLD reached a trading volume of 5503660 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $15.82 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on December 13, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on September 06, 2024, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise to $18, while Wells Fargo analysts kept a Overweight rating on FOLD stock.
The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.30, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 3.46. The Price to Book ratio for the last quarter was 9.70, with the Price to Cash per share for the same quarter was set at 0.81. Price to Free Cash Flow for FOLD in the course of the last twelve months was 1166.70 with Quick ratio for the last quarter at 2.47.
FOLD stock trade performance evaluation
Amicus Therapeutics Inc [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.44. With this latest performance, FOLD shares dropped by -17.46% in over the last four-week period, additionally sinking by -35.79% over the last 6 months – not to mention a drop of -35.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 38.94, with the RSI for the last a single of trading hit 39.06, and the three-weeks RSI is set at 38.36 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 7.13, while it was recorded at 6.23 for the last single week of trading, and 9.50 for the last 200 days.
Amicus Therapeutics Inc [FOLD]: An insightful look at the core fundamentals
Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.47 and a Current Ratio set at 3.34.
Amicus Therapeutics Inc [FOLD]: Institutional Ownership
The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 28.59 million shares, which is approximately 9.4111%. PERCEPTIVE ADVISORS LLC, holding 28.06 million shares of the stock with an approximate value of $$278.33 million in FOLD stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$271.81 million in FOLD stock with ownership which is approximately 9.0199%.
